Abstract:In this study, we have investigated 6 novel influenza‐derived peptides predicted to be restricted to the understudied HLA‐B*18:01 molecule. We identified that 3/6 of the novel peptides were immunogenic in samples from several donors and restricted to HLA‐B*18:01 as predicted and were further characterised. Objectives Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza‐derived peptides from internal structural and non‐structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA‐I). Each HLA‐I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell‐mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules. Methods Here, we assessed the immunogenicity of six recently published novel influenza‐derived peptides identified by mass‐spectrometry and predicted to bind to the prevalent HLA‐B*18:01 molecule. Results Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA‐B*18:01+ individuals and confirmed their HLA‐B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA‐B*18:01‐restricted NP219 peptide. Using X‐ray crystallography, we solved the first crystal structures of HLA‐B*18:01 presenting immunogenic influenza‐derived peptides. Finally, we dissected the first TCR repertoires specific for HLA‐B*18:01 restricted pathogen‐derived peptides, identifying private and restricted repertoires against each of the four peptides. Conclusion Overall the characterisation of these novel immunogenic peptides provides additional HLA‐B*18:01‐restricted vaccine targets derived from the Matrix protein 1 and potentially the non‐structural protein and the RNA polymerase catalytic subunit of influenza viruses.

Fighting flu: novel CD8+ T‐cell targets are required for future influenza vaccines

Opportunities and challenges for T cell-based influenza vaccines

Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact

A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A

Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine

Characterisation of novel influenza‐derived HLA‐B*18:01‐restricted epitopes

The race toward a universal influenza vaccine: Front runners and the future directions

Influenza vaccines: Past, present, and future

Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

How far have we reached in development of effective influenza vaccine?

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Towards a universal influenza vaccine: different approaches for one goal

Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine

Influenza vaccine: progress in a vaccine that elicits a broad immune response

Flu Universal Vaccines: New Tricks on an Old Virus

Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus

CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function